author-photo

F. Nolè

European Institute of Oncology

223

Papers

6210

Citations

Citation Trend

Filter By

Papers (157) Sort By

Journal Conference Others

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (153)
The effect of a treatment delay on outcome in metastatic renal cell carcinoma

2019 Urologic Oncology-seminars and Original Investigations
Show All
- Source
- Cite
- Save
Citations (4)
A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica

2019 Critical Reviews in Oncology Hematology
Show All
- Source
- Cite
- Save
Citations (2)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

2019 Critical Reviews in Oncology Hematology
Show All
- Source
- Cite
- Save
Citations (101)
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (165)
1094PClinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)